Previous Events

Are pharmaceutical IPRs a barrier to access to medicines or are they essential to it? Do pharmaceutical patents prevent or enhance pharmaceutical research and development? Are compulsory licenses a legitimate tool for price negotiations or are they a predatory mechanism aimed at circumventing the rights of developers? Is there any hope at all for multilateral IP negotiations and, if so, for whom? Are pharmaceutical IPRs a zero sum game or can they lead to win-win results?

The Gowers Review, published in 2006, proposes a fundamental review of IP protection in the UK. Its 54 recommendations affect issues such as copyright term, fair use, enforcement, patent and trade mark protection and the role of the Patent Office.
Managing Intellectual Property Magazine, in association with Lovells, and in collaboration with the Stockholm Network, hosted a unique discussion on the Gowers Review featuring panellists from industry and the law as well as Andrew Gowers himself.

Globalised markets: a positive for proponents of the free market; a source of social evils to the opponents. The debate is often confused in terms of winners and losers. What is the real impact of the integration of formerly poor, yet huge economies such as China and India into the world economy?

Far from being a threat to growth in the West, the issue requires clarification and proper assessment.

Charles Gave, CEO of a global financial analysis firm and an eminent analyst with extensive experience of international fund management, will interpret the trends of financial innovation and explain the positive impacts of market integration.

The business of creating, distributing and selling counterfeit pharmaceutical products is an unregulated, criminal and growing part of the global economy. There is one major difference between pharmaceutical counterfeiting and other underground industries: lives are at stake.

Coincidence or Crisis brings together some of the world’s leading experts to discuss the growth of counterfeit pharmaceuticals. It provides a comprehensive analysis of the core issues, while delimiting key strategies to tackle the problem.

Handeln med förfalskade läkemedel har ökat under de senaste åren, och även om Sverige hittills varit relativt förskonat vet vi inget om framtiden. Sätten att förfalska läkemedel är otaliga och risken att bli upptäckt liten. Att förfalskade läkemedel når Sverige via den vanliga läkemedelsimporten och i slutändan hamnar på de vanliga apotekens hyllor är ingen omöjlighet. Detta har exempelvis redan inträffat i Storbritannien.

Boken Coincidence or Crisis? beskriver problemet med läkemedelsförfalskning, dess omfattning och möjliga lösningar ur ett europeiskt perspektiv.

Boken presenteras av Graham Satchwell som är en av författarna. Efteråt följer en paneldiskussion om läget i Sverige och de internationella erfarenheterna. Hur allvarligt är problemet med illegala läkemedel och läkemedelsförfalskning och hur kan vi lära oss av andra länders erfarenheter?

Almost unthinkable 20 years ago, Sweden has seen rapid development of free schools in the past decade. Thanks to a voucher reform launched in 1993, anybody has the right to start pre-schools, primary, secondary and high schools. Money follows the pupil and schools may be run as cooperatives, foundations, companies or by individuals.

What are the limits and potential of free choice in education, and what is the impact on public schools of greater competition? This event will bring together Per Unckel, former Minister of Education in Sweden and author of the reform, and Etienne Verhack, Secretary General of the European Committee for Catholic Education, to discuss the challenges in the growing market for private education.

The business of creating, distributing and selling counterfeit pharmaceutical products is an unregulated, criminal and growing part of the global economy. There is one major difference between pharmaceutical counterfeiting and other underground industries: lives are at stake.

Coincidence or Crisis brings together some of the world’s leading experts to discuss the growth of counterfeit pharmaceuticals. It provides a comprehensive analysis of the core issues, while delimiting key strategies to tackle the problem.

What is David Cameron for? He downplays tax cuts, is socially liberal and believes in a muscular foreign policy (and voted for the Iraq war). He would like to reform public services to give consumers more choice, and to involve private companies and charities in providing them. Sound familiar? If so, is that a bad thing? After all, policies like these have just won three elections in a row. Will the new Cameron era be a break with the past or a return to true-blue values? Is Mr Cameron just a softer, pre-Thatcher Tory with a dollop of belief in the possibility of progress added? Can he create a vision for the future which his entire party can support, or will he only serve to divide the party further? And would Britain governed by a Cameron-led Conservative Party feel very different to Britain today?

The Stockholm Network in association with Managing Intellectual Property Magazine and The Progress & Freedom Foundation has developed a new and innovative statistical index aimed at measuring the strength of IP rights in the IT sector in different countries.

In this event, we will launch the IP-IT Index for the first time and present its rationale, methodology and specific components, as well as the scores of some of the leading markets

As businesses and consumers struggle to adjust to high energy prices and threats to supply, the European Commission and many EU member states are drawing up new national strategies for energy. The European Commission considers the liberalisation of EU electricity and gas markets to be a key part of its Lisbon agenda to improve the performance of the European economy. Commission President José Manuel Barroso and Energy Commissioner, Andris Piebalgs, hope that reforms favouring free markets and liberal institutions will provide the right framework for investment and trade.